Folate is one of the most heavily purchased vitamin actives in the world and one of the easiest to get wrong on paperwork. The word "folate" is a family name, not an ingredient. Two products can both claim 400 mcg of folate on the front panel and contain chemically different actives, in different salts, with different stability profiles and different permitted claim wording. This guide covers what to pin down before a folate product is ordered.

Folic acid and 5-MTHF are different actives

  • Folic acid — the synthetic, fully oxidised form. It is the most stable, the cheapest, and the only form for which the neural tube defect health claim has been established in most markets. It has no natural food equivalent.
  • L-5-methyltetrahydrofolate (5-MTHF, "methylfolate") — the predominant naturally circulating form. It is supplied as a stabilised salt, most commonly the calcium salt or the glucosamine salt, and the choice changes the potency per milligram and the label declaration.
  • Folinic acid — a further reduced form, used in some clinical and paediatric formulas.

If a brief says only "folate 400 mcg", it is not yet a specification. Ask for the active, the salt, the assay, and the label declaration — and put all four on the spec sheet.

The MTHFR question, handled carefully

Methylfolate's commercial pull comes from the MTHFR enzyme, which reduces dietary folate and folic acid to the circulating 5-MTHF form. Variants of the gene are common, and the popular argument is that some people convert folic acid less efficiently. That is a legitimate formulation rationale for choosing a reduced form — but it is not a claim you can print. Do not put MTHFR wording, gene-testing language, or any suggestion of treating a deficiency on a pack. Keep it an ingredient-selection decision and let the marketing copy stay on the ingredients.

5-MTHF is the harder active to keep stable

This is the practical reason the choice matters more than the headline number:

  • 5-MTHF is sensitive to oxidation, moisture, heat and light. Expect to specify an overage and to justify it with real-time and accelerated data on the finished product, not on the raw material alone.
  • Folic acid is far more forgiving and is the usual choice when the format is aggressive — a gummy cooked at temperature, for instance, or a liquid with a long shelf life.
  • The container is part of the formulation. An induction seal with a desiccant, or a moisture-barrier laminate, is often what lets a reduced folate hold specification for the full shelf life.
  • Because the actives are dosed in micrograms, blend uniformity is the real manufacturing risk. A low-dose active in a big tablet or a gummy is where content uniformity fails; ask what the manufacturer does about it.

Dosing: mcg DFE is not the same as mcg

Folate is declared on a different scale from most vitamins. The Dietary Folate Equivalent converts actives to a common basis, and folic acid carries a higher conversion factor than food folate because it is absorbed more completely. That means a product labelled "400 mcg DFE" of folic acid contains materially fewer micrograms of the actual compound than a consumer assumes. Decide up front whether your target is stated in mcg DFE or mcg of active, put that on the spec sheet, and keep the front panel and the nutrition panel consistent. This single ambiguity causes more artwork reprints than any other in the category.

Choosing the format

  • Tablets — the traditional home for low-microgram actives, because a small, uniform tablet is easy to make and easy to keep stable. This is where most methylfolate SKUs sit.
  • Capsules — good moisture protection, and the usual choice when folate is one component of a B-complex or prenatal blend.
  • Liquid drops — very popular for dose flexibility in this category. The stability burden shifts entirely to the solution: pH, preservative system and light-protective packaging all have to be settled with data.
  • Gummies — the hardest format for a reduced folate. Heat during manufacture and residual moisture during storage both work against 5-MTHF. If the brief is a gummy, expect folic acid or a significant overage.

Claims, warnings and market differences

  • In several markets a health claim linking folic acid to reduced risk of neural tube defects is permitted at a defined daily intake — and the wording is tied to folic acid specifically, not to folate generally. Verify whether a reduced form can carry the same claim before approving artwork.
  • Folate can mask the haematological signs of vitamin B12 deficiency, so B12 interaction wording is a standard labelling requirement in many markets.
  • Keep the pack itself to the product name, specification and count, and route every claim through an advisor who can sign it off for the destination market.

MOQ, sampling and lead times

A practical starting point with a manufacturer that supports small batches is MOQ 500 units per SKU, samples in 3–5 days, production shipped within 7 days, and a certificate of analysis with every batch.

How Haiyue Shengda works

We develop and fill capsules, softgels, gummies, tablets, liquid drops, powders, teas and personal-care formats in our own 5,000+ m² factory with 7 production lines and 34 machines, under FDA facility registration and HACCP, cGMP and ISO 22000. Custom formulations and outer-packaging design are free, with the first design sketch in about two hours. Browse our tablets, capsules and softgels and liquid drops ranges, read the FAQ, or contact us — we reply within one hour on working days.